MannKind's Afrezza approved

Share this article:
One small step for MannKind: inhalable insulin gets FDA nod
MannKind's Afrezza approved

MannKind has capped years of research and three FDA rejections with a positive: regulatory approval of its inhaled insulin, Afrezza.

The mealtime human insulin is for type 1 and type 2 diabetes patients, and type 1 patients are instructed to use it in tandem with long-acting insulin.

Last week's approval followed the regulator's April request for more time to ponder the data, and this request followed an unexpected endorsement by an FDA advisory panel this past spring. It was a surprise because pre-meeting documentation seemed to indicate the panel was not feeling favorable towards the drug.

The new drug includes a black-box warning which notes COPD and other chronic lung disease patients should stay away from Afrezza because it's been associated with acute bronchospasm. Griffin Securities analyst Keith Markey is not bothered by the warning, telling Bloomberg he considered it a “non-event,” because “MannKind never wanted to market it to people with COPD.”

The approval also includes post-marketing study requirements that will address topics including pediatric use and cardiovascular risk.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.